Those that have already been approved, including a PI3K inhibitor (alpelisib) and an mTOR inhibitor (everolimus), provide more options for patients with HR‐positive/HER2‐negative advanced breast cancer after disease progression with endocrine therapy. Here, ERBB2 is linked to breast cancer.